



The Clinical Trials Transformation Initiative 10 Year Anniversary

Draft Agenda of the Symposium on Feb. 6, 2018

DoubleTree by Hilton Hotel Bethesda-Washington, DC
8120 Wisconsin Ave., Bethesda, MD 20814

CTTI MISSION

To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials

MEETING OBJECTIVES:

- ▶ Discover how CTTI has influenced the clinical trials enterprise during the past decade.
- ▶ Hear from other organizations about the benefits of applying CTTI recommendations successfully.
- ▶ Learn how CTTI's current work will impact and shape clinical trials of the future.

FEBRUARY 6, 2018

8:30 a.m. Session I: Reflection

Session I Facilitator: Pamela Tenaerts, CTTI

- 8:30 a.m. Welcome and Introduction to CTTI
Pamela Tenaerts, CTTI
- 8:45 a.m. Welcome from the Executive Committee
Jacqueline Corrigan-Curay, FDA
- 8:55 a.m. Keynote Address
Scott Gottlieb, FDA (TBC)

9:30 a.m. Session II: Implementation and Impact – Quality by Design

Session II Facilitator: Martin Landray, University of Oxford

- 9:30 a.m. Reflection on Quality by Design
Robert Temple, FDA, CDER
Fergus Sweeney, European Medicines Agency (TBC)
- 9:45 a.m. Quality by Design Project Overview and Recommendations
Ann Meeker-O'Connell, Johnson & Johnson
- 10:00 a.m. Quality by Design Case Study
Julie Deitrich, Amgen
- 10:20 a.m. Discussion

10:45 a.m. Break and Poster Session

11:15 a.m. Session III: Implementation and Impact – Patient Groups & Clinical Trials

Session III Facilitator: Nancy Roach, Fight Colorectal Cancer

- 11:15 a.m. Reflection on Patient Engagement
Ken Getz, Tufts University
- 11:25 a.m. Patient Groups & Clinical Trials Project Overview and Recommendations
Bray Patrick-Lake, Duke Clinical Research Institute
- 11:40 a.m. Patient Groups & Clinical Trials Case Study
Ron Bartek, Friedreich's Ataxia Research Alliance
Jeff Sherman, Horizon Pharma
- 12:00 p.m. Discussion
- 12:30 p.m. Lunch and Poster Session *(Provided)*

FEBRUARY 6, 2018 (Continued)

1:30 p.m. Session IV: Implementation and Impact – Use of a Single IRB of Record

Session IV Facilitator: Joanne Less, FDA, OC

1:30 p.m. Reflection on Use of a Single IRB of Record
Jerry Menikoff, Office for Human Research Protections

1:40 p.m. Central IRB Project Overview and Recommendations
Soo Bang, Celgene (TBC)

1:55 p.m. Use of a Single IRB of Record Case Study
Hallie Kassan, Feinstein Institute for Medical Research

2:15 p.m. Discussion

2:45 p.m. Break and Poster Session

3:00 p.m. Session V: Envisioning the Future of Clinical Trials

Session V Facilitator: Rob Califf, Duke University

3:00 p.m. The Future of Clinical Trials
Rob Califf, Duke University / Verily

3:20 p.m. Discussion

4:00 p.m. Summary & Adjournment
Pamela Tenaerts, CTTI